InstitutionMD Anderson
Address1400 Pressler St
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Subbiah V, Coleman N, Piha-Paul SA, Tsimberidou AM, Janku F, Rodon J, Pant S, Dumbrava EE, Fu S, Hong DS, Zhang S, Sun M, Jiang Y, Roszik J, Song J, Yuan Y, Meric-Bernstam F, Naing A, Subbiah V, Coleman N, Piha-Paul SA, Tsimberidou AM, Janku F, Rodon J, Pant S, Dumbrava EEI, Fu S, Hong DS, Zhang S, Sun M, Jiang Y, Roszik J, Song J, Yuan Y, Meric-Bernstam F, Naing A. Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies. Cancer Res Commun. 2024 Feb 12; 4(2):378-387. PMID: 38126764; PMCID: PMC10860536.
      Citations: 1     
    2. Amaria R, Knisely A, Vining D, Kopetz S, Overman MJ, Javle M, Antonoff MB, Tzeng CD, Wolff RA, Pant S, Lito K, Rangel K, Fellman B, Yuan Y, Lu KH, Sakellariou-Thompson D, Haymaker CL, Forget MA, Hwu P, Bernatchez C, Jazaeri AA. Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. J Immunother Cancer. 2024 Feb 02; 12(2). PMID: 38309721; PMCID: PMC10840042.
      Citations:    Fields:    Translation:HumansCells
    3. Yuan Y, Zhou H, Liu S. Statistical and practical considerations in planning and conduct of dose-optimization trials. Clin Trials. 2024 Jan 19; 17407745231207085. PMID: 38243399.
      Citations:    Fields:    
    4. Taniguchi CM, Frakes JM, Aguilera TA, Palta M, Czito B, Bhutani MS, Colbert LE, Abi Jaoude J, Bernard V, Pant S, Tzeng CD, Kim DW, Malafa M, Costello J, Mathew G, Rebueno N, Koay EJ, Das P, Ludmir EB, Katz MHG, Wolff RA, Beddar S, Sawakuchi GO, Moningi S, Slack Tidwell RS, Yuan Y, Thall PF, Beardsley RA, Holmlund J, Herman JM, Hoffe SE. Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial. Lancet Oncol. 2023 Dec; 24(12):1387-1398. PMID: 38039992.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    5. Hinchcliff EM, Knisely A, Adjei N, Fellman B, Yuan Y, Patel A, Xu C, Westin SN, Sood AK, Soliman PT, Shafer A, Fleming ND, Gershenson DM, Vikram R, Bathala T, Vining D, Ganeshan DM, Lu KH, Sun CC, Meyer LA, Jazaeri AA. Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer. Cancer. 2023 Nov 27. PMID: 38009662.
      Citations:    Fields:    
    6. Thall PF, Zang Y, Chapple AG, Yuan Y, Lin R, Marin D, Msaouel P, Thall PF, Zang Y, Chapple AG, Yuan Y, Lin R, Marin D, Msaouel P. Novel Clinical Trial Designs with Dose Optimization to Improve Long-term Outcomes. Clin Cancer Res. 2023 Nov 14; 29(22):4549-4554. PMID: 37725573; PMCID: PMC10841062.
      Citations:    Fields:    Translation:Humans
    7. Stephen B, Hajjar J, Sarda S, Duose DY, Conroy JM, Morrison C, Alshawa A, Xu M, Zarifa A, Patel SP, Yuan Y, Kwiatkowski E, Wang L, Rodon Ahnert J, Fu S, Meric-Bernstam F, Lowman GM, Looney T, Naing A. T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy. J Immunother Cancer. 2023 08; 11(8). PMID: 37604642; PMCID: PMC10445351.
      Citations: 2     Fields:    Translation:Humans
    8. Gregory TA, Mastall M, Lin H, Hess KR, Yuan Y, Martin-Bejarano Garcia M, Fuller GN, Alfaro KD, Gule-Monroe MK, Huse JT, Khatua S, Rao G, Sandberg DI, Wefel JS, Yeboa DN, Paulino AC, McGovern SL, Zaky W, Mahajan A, Suki D, Weathers SP, Harrison RA, de Groot JF, Puduvalli VK, Penas-Prado M, Majd NK. Characterization of recurrence patterns and outcomes of medulloblastoma in adults: The University of Texas MD Anderson Cancer Center experience. Neurooncol Adv. 2023 Jan-Dec; 5(1):vdad032. PMID: 37114244; PMCID: PMC10129387.
    9. Zhao Y, Li D, Liu R, Yuan Y. Bayesian optimal phase II designs with dual-criterion decision making. Pharm Stat. 2023 Jul-Aug; 22(4):605-618. PMID: 36871961.
      Citations:    Fields:    Translation:Humans
    10. Son J, Lin HY, Fu S, Biter AB, Dumbrava EE, Karp DD, Naing A, Pant S, Piha-Paul SA, Rodon J, Subbiah V, Tsimberidou AM, Yap TA, Frumovitz MM, Jazaeri AA, Ramirez PT, Westin SN, Yuan Y, Meric-Bernstam F, Hong DS. Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer. J Immunother Precis Oncol. 2023 Feb; 6(1):10-18. PMID: 36751659; PMCID: PMC9888522.
    11. Raghav K, Kopetz S, Yuan Y. Reply to Y. Yu et al. J Clin Oncol. 2023 03 01; 41(7):1495-1496. PMID: 36595731.
      Citations:    Fields:    
    12. Fu S, Yao S, Yuan Y, Previs RA, Elias AD, Carvajal RD, George TJ, Yuan Y, Yu L, Westin SN, Xing Y, Dumbrava EE, Karp DD, Piha-Paul SA, Tsimberidou AM, Ahnert JR, Takebe N, Lu K, Keyomarsi K, Meric-Bernstam F. Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification. J Clin Oncol. 2023 03 20; 41(9):1725-1734. PMID: 36469840; PMCID: PMC10489509.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    13. Yuan Y, Zhao Y. Commentary on "Improving the performance of Bayesian logistic regression model with overdose control in oncology dose-finding studies". Stat Med. 2022 Nov 30; 41(27):5484-5490. PMID: 36394102.
      Citations:    Fields:    Translation:Humans
    14. Son J, Hsieh RC, Lin HY, Krause KJ, Yuan Y, Biter AB, Welsh J, Curran MA, Hong DS. Inhibition of the CD47-SIRPa axis for cancer therapy: A systematic review and meta-analysis of emerging clinical data. Front Immunol. 2022; 13:1027235. PMID: 36439116; PMCID: PMC9691650.
      Citations: 1     Fields:    Translation:HumansCells
    15. Zhou Y, Zhao Y, Cicconetti G, Mu Y, Yuan Y, Wang L, Penugonda S, Salman Z. AIDE: Adaptive intrapatient dose escalation designs to accelerate Phase I clinical trials. Pharm Stat. 2023 03; 22(2):300-311. PMID: 36333972.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    16. Scheurer ME, Zhou R, Gilbert MR, Bondy ML, Sulman EP, Yuan Y, Liu Y, Vera E, Wendland MM, Youssef EF, Stieber VW, Komaki RR, Flickinger JC, Kenyon LC, Robins HI, Hunter GK, Crocker IR, Chao ST, Pugh SL, Armstrong TS. Germline polymorphisms in MGMT associated with temozolomide-related myelotoxicity risk in patients with glioblastoma treated on NRG Oncology/RTOG 0825. Neurooncol Adv. 2022 Jan-Dec; 4(1):vdac152. PMID: 36299794; PMCID: PMC9587696.
      Citations: 1     
    17. Lin R, Shi H, Yin G, Thall PF, Yuan Y, Flowers CR. BAYESIAN HIERARCHICAL RANDOM-EFFECTS META-ANALYSIS AND DESIGN OF PHASE I CLINICAL TRIALS. Ann Appl Stat. 2022 Dec; 16(4):2481-2504. PMID: 36329718; PMCID: PMC9624503.
    18. Ng SP, Cardenas CE, Bahig H, Elgohari B, Wang J, Johnson JM, Moreno AC, Shah SJ, Garden AS, Phan J, Gunn GB, Frank SJ, Ding Y, Na L, Yuan Y, Urbauer D, Mohamed ASR, Rosenthal DI, Morrison WH, MacManus MP, Fuller CD. Changes in Apparent Diffusion Coefficient (ADC) in Serial Weekly MRI during Radiotherapy in Patients with Head and Neck Cancer: Results from the PREDICT-HN Study. Curr Oncol. 2022 08 31; 29(9):6303-6313. PMID: 36135064; PMCID: PMC9498049.
    19. How JA, Jazaeri AA, Fu S, Rodon Ahnert J, Gong J, Stephen B, Ferreira Dalla Pria H, Bhosale P, Johnson A, Yuan Y, Meric-Bernstam F, Naing A. Clinical Outcomes of Patients with Recurrent Microsatellite-Stable Endometrial Cancer in Early-Phase Immunotherapy Clinical Trials. Cancers (Basel). 2022 Jul 29; 14(15). PMID: 35954359; PMCID: PMC9367373.
    20. Qing Y, Thall PF, Yuan Y. A Bayesian piecewise exponential phase II design for monitoring a time-to-event endpoint. Pharm Stat. 2023 01; 22(1):34-44. PMID: 35851545; PMCID: PMC10150550.
      Citations:    Fields:    
    21. Zhao Y, Tang RS, Du Y, Yuan Y. A Bayesian platform trial design to simultaneously evaluate multiple drugs in multiple indications with mixed endpoints. Biometrics. 2023 06; 79(2):1459-1471. PMID: 35546501.
      Citations:    Fields:    
    22. Msaouel P, Goswami S, Thall PF, Wang X, Yuan Y, Jonasch E, Gao J, Campbell MT, Shah AY, Corn PG, Tam AL, Ahrar K, Rao P, Sircar K, Cohen L, Basu S, Duan F, Jindal S, Zhang Y, Chen H, Yadav SS, Shazer R, Der-Torossian H, Allison JP, Sharma P, Tannir NM. A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. Sci Transl Med. 2022 04 20; 14(641):eabm6420. PMID: 35442707.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    23. Chaftari AM, Hachem R, Malek AE, Mulanovich VE, Szvalb AD, Jiang Y, Yuan Y, Ali S, Deeba R, Chaftari P, Raad I. A Prospective Randomized Study Comparing Ceftolozane/Tazobactam to Standard of Care in the Management of Neutropenia and Fever in Patients With Hematological Malignancies. Open Forum Infect Dis. 2022 Jun; 9(6):ofac079. PMID: 35663286; PMCID: PMC9154317.
    24. Garmezy B, Gheeya J, Lin HY, Huang Y, Kim T, Jiang X, Thein KZ, Zeineddine F, Wang W, Shaw KR, Rodon J, Shen JP, Yuan Y, Meric-Bernstam F, Chen K, Yap TA, Pili? PG. Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers. JCO Precis Oncol. 2022 02; 6:e2100267. PMID: 35108036; PMCID: PMC8820927.
      Citations: 1     Fields:    Translation:Humans
    25. Zhou Y, Lin R, Lee JJ, Li D, Wang L, Li R, Yuan Y. TITE-BOIN12: A Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy. Stat Med. 2022 05 20; 41(11):1918-1931. PMID: 35098585; PMCID: PMC9199061.
      Citations: 2     Fields:    Translation:Humans
    26. Carmack CL, Parker NH, Demark-Wahnefried W, Shely L, Baum G, Yuan Y, Giordano SH, Rodriguez-Bigas M, Pettaway C, Basen-Engquist K. Healthy Moves to Improve Lifestyle Behaviors of Cancer Survivors and Their Spouses: Feasibility and Preliminary Results of Intervention Efficacy. Nutrients. 2021 Dec 14; 13(12). PMID: 34960013; PMCID: PMC8709140.
      Citations: 1     Fields:    Translation:Humans
    27. Prokhorov AV, Calabro KS, Arya A, Russell S, Czerniak KW, Botello GC, Chen M, Yuan Y, Perez A, Vidrine DJ, Perry CL, Khalil GE. Mobile Text Messaging for Tobacco Risk Communication Among Young Adult Community College Students: Randomized Trial of Project Debunk. JMIR Mhealth Uhealth. 2021 11 24; 9(11):e25618. PMID: 34822339; PMCID: PMC8663493.
      Citations:    Fields:    Translation:HumansAnimals
    28. Walker JG, Armstrong TS, O'Brien BJ, Gilbert MR, Casarez RL, Fagundes C, Heijnen CJ, Andersen CR, Yuan Y, Wu J, LoBiondo-Wood G. Associations of meaning of illness with psychosocial, clinical, and immunological characteristics in patients with Leptomeningeal metastasis. Compr Psychoneuroendocrinol. 2021 Nov; 8:100099. PMID: 35757676; PMCID: PMC9216264.
    29. van Dijk LV, Frank SJ, Yuan Y, Gunn B, Moreno AC, Mohamed ASR, Preston KE, Qing Y, Spiotto MT, Morrison WH, Lee A, Phan J, Garden AS, Rosenthal DI, Langendijk JA, Fuller CD. Proton Image-guided Radiation Assignment for Therapeutic Escalation via Selection of locally advanced head and neck cancer patients [PIRATES]: A Phase I safety and feasibility trial of MRI-guided adaptive particle radiotherapy. Clin Transl Radiat Oncol. 2022 Jan; 32:35-40. PMID: 34841093; PMCID: PMC8606299.
    30. Tidwell RSS, Thall PF, Yuan Y. Lessons Learned From Implementing a Novel Bayesian Adaptive Dose-Finding Design in Advanced Pancreatic Cancer. JCO Precis Oncol. 2021; 5. PMID: 34805718; PMCID: PMC8594665.
      Citations:    Fields:    Translation:Humans
    31. Phillips LM, Li S, Gumin J, Daou M, Ledbetter D, Yang J, Singh S, Parker Kerrigan BC, Hossain A, Yuan Y, Gomez-Manzano C, Fueyo J, Lang FF. An immune-competent, replication-permissive Syrian Hamster glioma model for evaluating Delta-24-RGD oncolytic adenovirus. Neuro Oncol. 2021 11 02; 23(11):1911-1921. PMID: 34059921; PMCID: PMC8563315.
      Citations: 1     Fields:    Translation:AnimalsCells
    32. Melendez B, Shah S, Jiang Y, Dottino J, Watson E, Pearce H, Borthwick M, Schmandt RE, Zhang Q, Cumpian K, Celestino J, Fellman B, Yuan Y, Lu KH, Mikos AG, Yates MS. Novel polymer-based system for intrauterine delivery of everolimus for anti-cancer applications. J Control Release. 2021 11 10; 339:521-530. PMID: 34648891; PMCID: PMC8650567.
      Citations:    Fields:    Translation:Animals
    33. Westin SN, Labrie M, Litton JK, Blucher A, Fang Y, Vellano CP, Marszalek JR, Feng N, Ma X, Creason A, Fellman B, Yuan Y, Lee S, Kim TB, Liu J, Chelariu-Raicu A, Chen TH, Kabil N, Soliman PT, Frumovitz M, Schmeler KM, Jazaeri A, Lu KH, Murthy R, Meyer LA, Sun CC, Sood AK, Coleman RL, Mills GB. Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. Clin Cancer Res. 2021 12 01; 27(23):6354-6365. PMID: 34518313; PMCID: PMC8639651.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    34. Patel RR, He K, Barsoumian HB, Chang JY, Tang C, Verma V, Comeaux N, Chun SG, Gandhi S, Truong MT, Erasmus JJ, Hong DS, Lee PP, Ning MS, Nguyen QN, Heymach JV, Altan M, Blumenschein G, Fossella FV, Sezen D, Chen D, Carter BW, Davies MA, Glitza IC, Diab A, Ferrarotto R, Cabanillas ME, Yuan Y, Shah SJ, Parra ER, Sun B, Cortez MA, Welsh JW. High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial. Radiother Oncol. 2021 09; 162:60-67. PMID: 34237343.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    35. Ferrarotto R, Amit M, Nagarajan P, Rubin ML, Yuan Y, Bell D, El-Naggar AK, Johnson JM, Morrison WH, Rosenthal DI, Glisson BS, Johnson FM, Lu C, Mott FE, Esmaeli B, Diaz EM, Gidley PW, Goepfert RP, Lewis CM, Weber RS, Wargo JA, Basu S, Duan F, Yadav SS, Sharma P, Allison JP, Myers JN, Gross ND. Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2021 08 15; 27(16):4557-4565. PMID: 34187851; PMCID: PMC8711237.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    36. Majd NK, Mastall M, Lin H, Dibaj SS, Hess KR, Yuan Y, Fuller GN, Alfaro KD, Gule-Monroe MK, Huse JT, Khatua S, Rao G, Sandberg DI, Wefel JS, Yeboa DN, Paulino AC, McGovern SL, Zaky W, Mahajan A, Suki D, Weathers SP, Harriso RA, De Groo JF, Puduvalli VK, Penas-Prado M, Garcia MM. Clinical characterization of adult medulloblastoma and the effect of first-line therapies on outcome; The MD Anderson Cancer Center experience. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab079. PMID: 34377987; PMCID: PMC8350154.
      Citations: 1     
    37. Jiang L, Nie L, Yan F, Yuan Y. Optimal Bayesian hierarchical model to accelerate the development of tissue-agnostic drugs and basket trials. Contemp Clin Trials. 2021 08; 107:106460. PMID: 34098036.
      Citations:    Fields:    Translation:Humans
    38. Yuan Y, Wu J, Gilbert MR. BOIN: a novel Bayesian design platform to accelerate early phase brain tumor clinical trials. Neurooncol Pract. 2021 Dec; 8(6):627-638. PMID: 34777832; PMCID: PMC8579094.
    39. Zhou Y, Lee JJ, Wang S, Bailey S, Yuan Y. Incorporating historical information to improve phase I clinical trials. Pharm Stat. 2021 11; 20(6):1017-1034. PMID: 33793044.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    40. Jiang L, Li R, Yan F, Yap TA, Yuan Y. Shotgun: A Bayesian seamless phase I-II design to accelerate the development of targeted therapies and immunotherapy. Contemp Clin Trials. 2021 05; 104:106338. PMID: 33711459; PMCID: PMC8180491.
      Citations:    Fields:    Translation:Humans
    41. How JA, Jazaeri AA, Fellman B, Daniels MS, Penn S, Solimeno C, Yuan Y, Schmeler K, Lanchbury JS, Timms K, Lu KH, Yates MS. Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer. Cancers (Basel). 2021 Feb 24; 13(5). PMID: 33668244; PMCID: PMC7956737.
      Citations: 8     
    42. Coleman RL, Hu W, Soliman P, Nick A, Ramirez PT, Westin SN, Garcia ME, Zhu Z, Palancia J, Fellman BM, Yuan Y, Ram P, Bischoff F, Schmeler K, Bodurka D, Meyer LA, Sood AK. Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study. Gynecol Oncol. 2021 04; 161(1):104-112. PMID: 33551196.
      Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
    43. Zhou Y, Lin R, Kuo YW, Lee JJ, Yuan Y. BOIN Suite: A Software Platform to Design and Implement Novel Early-Phase Clinical Trials. JCO Clin Cancer Inform. 2021 01; 5:91-101. PMID: 33439726; PMCID: PMC8462603.
      Citations: 5     Fields:    Translation:Humans
    44. Lin R, Thall PF, Yuan Y. BAGS: A Bayesian Adaptive Group Sequential Trial Design With Subgroup-Specific Survival Comparisons. J Am Stat Assoc. 2021; 116(533):322-334. PMID: 35582047; PMCID: PMC9109248.
    45. Lin R, Zhou Y, Yan F, Li D, Yuan Y. BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted Therapies. JCO Precis Oncol. 2020; 4. PMID: 33283133; PMCID: PMC7713525.
      Citations: 7     Fields:    
    46. Lin R, Yuan Y. Time-to-event model-assisted designs for dose-finding trials with delayed toxicity. Biostatistics. 2020 10 01; 21(4):807-824. PMID: 30984972; PMCID: PMC8559898.
      Citations: 9     Fields:    Translation:Humans
    47. Zhou Y, Li R, Yan F, Lee JJ, Yuan Y. A comparative study of Bayesian optimal interval (BOIN) design with interval 3+3 (i3+3) design for phase I oncology dose-finding trials. Stat Biopharm Res. 2021; 13(2):147-155. PMID: 34249223; PMCID: PMC8261789.
    48. Dottino JA, Zhang Q, Loose DS, Fellman B, Melendez BD, Borthwick MS, McKenzie LJ, Yuan Y, Yang RK, Broaddus RR, Lu KH, Soliman PT, Yates MS. Endometrial biomarkers in premenopausal women with obesity: an at-risk cohort. Am J Obstet Gynecol. 2021 03; 224(3):278.e1-278.e14. PMID: 32835719; PMCID: PMC7897335.
      Citations: 1     Fields:    Translation:Humans
    49. Westin SN, Fellman B, Sun CC, Broaddus RR, Woodall ML, Pal N, Urbauer DL, Ramondetta LM, Schmeler KM, Soliman PT, Fleming ND, Burzawa JK, Nick AM, Milbourne AM, Yuan Y, Lu KH, Bodurka DC, Coleman RL, Yates MS. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. Am J Obstet Gynecol. 2021 02; 224(2):191.e1-191.e15. PMID: 32805208; PMCID: PMC7855308.
      Citations: 13     Fields:    Translation:HumansCellsCTClinical Trials
    50. Abi Jaoude J, Kouzy R, Minsky BD, Fuller CD, Yuan Y, Do KA, Taniguchi CM, Ludmir EB. Sponsor-involved statistical analyses in Phase III cancer clinical trials. Int J Cancer. 2020 12 15; 147(12):3579-3581. PMID: 32621758; PMCID: PMC8460289.
      Citations:    Fields:    Translation:Humans
    51. de Groot J, Penas-Prado M, Alfaro-Munoz K, Hunter K, Pei BL, O'Brien B, Weathers SP, Loghin M, Kamiya Matsouka C, Yung WKA, Mandel J, Wu J, Yuan Y, Zhou S, Fuller GN, Huse J, Rao G, Weinberg JS, Prabhu SS, McCutcheon IE, Lang FF, Ferguson SD, Sawaya R, Colen R, Yadav SS, Blando J, Vence L, Allison J, Sharma P, Heimberger AB. Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro Oncol. 2020 04 15; 22(4):539-549. PMID: 31755915; PMCID: PMC7158647.
      Citations: 41     Fields:    Translation:HumansCells
    52. Lin R, Thall PF, Yuan Y. A Phase I-II Basket Trial Design to Optimize Dose-Schedule Regimes Based on Delayed Outcomes. Bayesian Anal. 2021 Mar; 16(1):179-202. PMID: 34267857; PMCID: PMC8277108.
      Citations: 1     
    53. Lin R, Coleman RL, Yuan Y. TOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer Immunotherapy. J Natl Cancer Inst. 2020 01 01; 112(1):38-45. PMID: 30924863; PMCID: PMC8204709.
      Citations: 5     Fields:    Translation:Humans
    54. Yuan Y, Lee JJ, Hilsenbeck SG. Model-Assisted Designs for Early-Phase Clinical Trials: Simplicity Meets Superiority. JCO Precis Oncol. 2019; 3. PMID: 32923856; PMCID: PMC7446379.
      Citations: 7     Fields:    
    55. Zhou Y, Lee JJ, Yuan Y. A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies. Stat Med. 2019 12 10; 38(28):5299-5316. PMID: 31621952; PMCID: PMC7927960.
      Citations: 9     Fields:    Translation:Humans
    56. Lin R, Thall PF, Yuan Y. An adaptive trial design to optimize dose-schedule regimes with delayed outcomes. Biometrics. 2020 03; 76(1):304-315. PMID: 31273750; PMCID: PMC6942642.
      Citations: 2     Fields:    Translation:Humans
    57. Jiang H, Shin DH, Nguyen TT, Fueyo J, Fan X, Henry V, Carrillo CC, Yi Y, Alonso MM, Collier TL, Yuan Y, Lang FF, Gomez-Manzano C. Localized Treatment with Oncolytic Adenovirus Delta-24-RGDOX Induces Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas. Clin Cancer Res. 2019 11 15; 25(22):6801-6814. PMID: 31455679; PMCID: PMC6858961.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    58. Tidwell RSS, Peng SA, Chen M, Liu DD, Yuan Y, Lee JJ. Bayesian clinical trials at The University of Texas MD Anderson Cancer Center: An update. Clin Trials. 2019 12; 16(6):645-656. PMID: 31450957; PMCID: PMC6904523.
      Citations: 3     Fields:    Translation:Humans
    59. Zhang C, Martinez-Ledesma E, Gao F, Zhang W, Ding J, Wu S, Li X, Wu J, Yuan Y, Koul D, Alfred Yung WK. Wild-type TP53 defined gamma-secretase inhibitor sensitivity and synergistic activity with doxorubicin in GSCs. Am J Cancer Res. 2019; 9(8):1734-1745. PMID: 31497354; PMCID: PMC6726980.
      Citations: 3     
    60. Lin R, Yuan Y. On the relative efficiency of model-assisted designs: a conditional approach. J Biopharm Stat. 2019; 29(4):648-662. PMID: 31258039; PMCID: PMC6733273.
      Citations: 1     Fields:    Translation:Humans
    61. Harrison RA, Anderson MD, Cachia D, Kamiya-Matsuoka C, Weathers SS, O'Brien BJ, Penas-Prado M, Yung WKA, Wu J, Yuan Y, de Groot JF. Clinical trial participation of patients with glioblastoma at The University of Texas MD Anderson Cancer Center. Eur J Cancer. 2019 05; 112:83-93. PMID: 30951926.
      Citations: 7     Fields:    Translation:Humans
    62. Zhu H, Chen K, Luo X, Yuan Y, Wang JL. FMEM: Functional Mixed Effects Models for Longitudinal Functional Responses. Stat Sin. 2019; 29(4):2007-2033. PMID: 31745381; PMCID: PMC6863349.
      Citations: 3     
    63. Zhou H, Yuan Y, Nie L. Accuracy, Safety, and Reliability of Novel Phase I Designs-Response. Clin Cancer Res. 2018 11 01; 24(21):5483-5484. PMID: 30385656.
      Citations: 3     Fields:    
    64. Murray TA, Yuan Y, Thall PF. A Bayesian Machine Learning Approach for Optimizing Dynamic Treatment Regimes. J Am Stat Assoc. 2018; 113(523):1255-1267. PMID: 30739965; PMCID: PMC6366650.
      Citations: 2     
    65. Wilson Dib R, Chaftari AM, Hachem RY, Yuan Y, Dandachi D, Raad II. Catheter-Related Staphylococcus aureus Bacteremia and Septic Thrombosis: The Role of Anticoagulation Therapy and Duration of Intravenous Antibiotic Therapy. Open Forum Infect Dis. 2018 Oct; 5(10):ofy249. PMID: 30377625; PMCID: PMC6201151.
      Citations: 7     
    66. Ng SP, Bahig H, Wang J, Cardenas CE, Lucci A, Hall CS, Meas S, Sarli VN, Yuan Y, Urbauer DL, Ding Y, Ikner S, Dinh V, Elgohari BA, Johnson JM, Skinner HD, Gunn GB, Garden AS, Phan J, Rosenthal DI, Morrison WH, Frank SJ, Hutcheson KA, Mohamed ASR, Lai SY, Ferrarotto R, MacManus MP, Fuller CD. Predicting treatment Response based on Dual assessment of magnetic resonance Imaging kinetics and Circulating Tumor cells in patients with Head and Neck cancer (PREDICT-HN): matching 'liquid biopsy' and quantitative tumor modeling. BMC Cancer. 2018 Sep 19; 18(1):903. PMID: 30231854; PMCID: PMC6148797.
      Citations: 6     Fields:    Translation:HumansCells
    67. Han M, Gao H, Xie J, Yuan YP, Yuan Q, Gao MQ, Liu KL, Chen XH, Han YT, Han ZW. Hispidulin induces ER stress-mediated apoptosis in human hepatocellular carcinoma cells in vitro and in vivo by activating AMPK signaling pathway. Acta Pharmacol Sin. 2019 May; 40(5):666-676. PMID: 30218072; PMCID: PMC6786425.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    68. Bahig H, Yuan Y, Mohamed ASR, Brock KK, Ng SP, Wang J, Ding Y, Hutcheson K, McCulloch M, Balter PA, Lai SY, Al-Mamgani A, Sonke JJ, van der Heide UA, Nutting C, Li XA, Robbins J, Awan M, Karam I, Newbold K, Harrington K, Oelfke U, Bhide S, Philippens MEP, Terhaard CHJ, McPartlin AJ, Blanchard P, Garden AS, Rosenthal DI, Gunn GB, Phan J, Cazoulat G, Aristophanous M, McSpadden KK, Garcia JA, van den Berg CAT, Raaijmakers CPJ, Kerkmeijer L, Doornaert P, Blinde S, Frank SJ, Fuller CD. Magnetic Resonance-based Response Assessment and Dose Adaptation in Human Papilloma Virus Positive Tumors of the Oropharynx treated with Radiotherapy (MR-ADAPTOR): An R-IDEAL stage 2a-2b/Bayesian phase II trial. Clin Transl Radiat Oncol. 2018 Nov; 13:19-23. PMID: 30386824; PMCID: PMC6204434.
      Citations: 20     
    69. Liu S, Guo B, Yuan Y. A Bayesian Phase I/II Trial Design for Immunotherapy. J Am Stat Assoc. 2018; 113(523):1016-1027. PMID: 31741544; PMCID: PMC6860919.
      Citations: 7     
    70. Yuan Y, Lin R, Li D, Nie L, Warren KE. Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials. Clin Cancer Res. 2018 10 15; 24(20):4921-4930. PMID: 29769209; PMCID: PMC6191365.
      Citations: 21     Fields:    Translation:Humans
    71. Yates MS, Coletta AM, Zhang Q, Schmandt RE, Medepalli M, Nebgen D, Soletsky B, Milbourne A, Levy E, Fellman B, Urbauer D, Yuan Y, Broaddus RR, Basen-Engquist K, Lu K. Prospective Randomized Biomarker Study of Metformin and Lifestyle Intervention for Prevention in Obese Women at Increased Risk for Endometrial Cancer. Cancer Prev Res (Phila). 2018 08; 11(8):477-490. PMID: 29716897; PMCID: PMC6072574.
      Citations: 13     Fields:    Translation:Humans
    72. Han M, Gao H, Ju P, Gao MQ, Yuan YP, Chen XH, Liu KL, Han YT, Han ZW. Hispidulin inhibits hepatocellular carcinoma growth and metastasis through AMPK and ERK signaling mediated activation of PPAR?. Biomed Pharmacother. 2018 Jul; 103:272-283. PMID: 29656183.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    73. Zhou H, Murray TA, Pan H, Yuan Y. Comparative review of novel model-assisted designs for phase I clinical trials. Stat Med. 2018 06 30; 37(14):2208-2222. PMID: 29682777.
      Citations: 17     Fields:    Translation:Humans
    74. Zhou H, Yuan Y, Nie L. Accuracy, Safety, and Reliability of Novel Phase I Trial Designs. Clin Cancer Res. 2018 09 15; 24(18):4357-4364. PMID: 29661774.
      Citations: 24     Fields:    Translation:Humans
    75. Mandel JJ, Yust-Katz S, Patel AJ, Cachia D, Liu D, Park M, Yuan Y, Kent TA, de Groot JF. Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma. Neuro Oncol. 2018 01 10; 20(1):113-122. PMID: 29016865; PMCID: PMC5761583.
      Citations: 20     Fields:    Translation:Humans
    76. Ma CL, Li XD, Sun XR, Zhao DB, Yuan YP, Yu YH. Using 18F-fluorodeoxyglucose positron emission tomography/computed tomography to estimate the length of gross tumor and involvement of lymph nodes in esophagogastric junction carcinoma. J Cancer Res Ther. 2018; 14(4):896-901. PMID: 29970673.
      Citations: 2     Fields:    Translation:Humans
    77. Harano K, Kogawa T, Wu J, Yuan Y, Cohen EN, Lim B, Reuben JM, Ueno NT. Thrombocytosis as a prognostic factor in inflammatory breast cancer. Breast Cancer Res Treat. 2017 Dec; 166(3):819-832. PMID: 28831670.
      Citations: 9     Fields:    Translation:HumansCells
    78. Zhou H, Lee JJ, Yuan Y. BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints. Stat Med. 2017 Sep 20; 36(21):3302-3314. PMID: 28589563.
      Citations: 15     Fields:    Translation:Humans
    79. Jiang H, Rivera-Molina Y, Gomez-Manzano C, Clise-Dwyer K, Bover L, Vence LM, Yuan Y, Lang FF, Toniatti C, Hossain MB, Fueyo J. Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination. Cancer Res. 2017 07 15; 77(14):3894-3907. PMID: 28566332; PMCID: PMC5549681.
      Citations: 74     Fields:    Translation:HumansAnimalsCells
    80. Murray TA, Thall PF, Yuan Y, McAvoy S, Gomez DR. Robust treatment comparison based on utilities of semi-competing risks in non-small-cell lung cancer. J Am Stat Assoc. 2017; 112:11-23. PMID: 28943681; PMCID: PMC5607962.
      Citations: 7     
    81. Katz LH, Advani S, Burton-Chase AM, Fellman B, Polivka KM, Yuan Y, Lynch PM, Peterson SK. Cancer screening behaviors and risk perceptions among family members of colorectal cancer patients with unexplained mismatch repair deficiency. Fam Cancer. 2017 04; 16(2):231-237. PMID: 27832499; PMCID: PMC5945287.
      Citations: 3     Fields:    Translation:HumansCells
    82. Pakish JB, Zhang Q, Chen Z, Liang H, Chisholm GB, Yuan Y, Mok SC, Broaddus RR, Lu KH, Yates MS. Immune Microenvironment in Microsatellite-Instable Endometrial Cancers: Hereditary or Sporadic Origin Matters. Clin Cancer Res. 2017 Aug 01; 23(15):4473-4481. PMID: 28264871; PMCID: PMC5540763.
      Citations: 36     Fields:    Translation:HumansCells
    83. Pan H, Yuan Y, Xia J. A Calibrated Power Prior Approach to Borrow Information from Historical Data with Application to Biosimilar Clinical Trials. J R Stat Soc Ser C Appl Stat. 2017 11; 66(5):979-996. PMID: 29249839; PMCID: PMC5726611.
      Citations: 7     
    84. Yuan Y, Sturgis EM, Zhu L, Lu M, Li Y, Wei Q, Li G. A functional variant at the miRNA binding site in E2F1 gene is associated with risk and tumor HPV16 status of oropharynx squamous cell carcinoma. Mol Carcinog. 2017 03; 56(3):1100-1106. PMID: 27677255.
      Citations: 5     Fields:    Translation:HumansCells
    85. Yuan Y, Hess KR, Hilsenbeck SG, Gilbert MR. Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials. Clin Cancer Res. 2016 Sep 01; 22(17):4291-301. PMID: 27407096; PMCID: PMC5047439.
      Citations: 37     Fields:    Translation:Humans
    86. Zhang L, Yuan Y, Lu KH, Zhang L. Identification of recurrent focal copy number variations and their putative targeted driver genes in ovarian cancer. BMC Bioinformatics. 2016 May 26; 17(1):222. PMID: 27230211; PMCID: PMC4881176.
      Citations: 7     Fields:    Translation:Humans
    87. Murray TA, Thall PF, Yuan Y. Utility-based designs for randomized comparative trials with categorical outcomes. Stat Med. 2016 10 30; 35(24):4285-4305. PMID: 27189672; PMCID: PMC5048520.
      Citations: 7     Fields:    Translation:Humans
    88. Yuan Y, Guo B, Munsell M, Lu K, Jazaeri A. MIDAS: a practical Bayesian design for platform trials with molecularly targeted agents. Stat Med. 2016 09 30; 35(22):3892-906. PMID: 27112322; PMCID: PMC5012931.
      Citations: 10     Fields:    Translation:Humans
    89. Jiang Y, Zhang J, Zheng X, Chen Y, Thompson EJ, Weinstein JN, Yuan Y, Broaddus R, Tannir NM, Lu KH, Su X, Malouf GG, Spano JP, Khayat D. Long non-coding RNA profiling links subgroup classification of endometrioid endometrial carcinomas with trithorax and polycomb complex aberrations. Oncotarget. 2015 Nov 24; 6(37):39865-76. PMID: 26431491; PMCID: PMC4741866.
      Citations: 10     Fields:    Translation:HumansCells
    90. Hamza MA, Kamiya-Matsuoka C, Liu D, Yuan Y, Puduvalli VK. Outcome of patients with malignant glioma and synchronous or metachronous non-central nervous system primary neoplasms. J Neurooncol. 2016 Feb; 126(3):527-33. PMID: 26566652; PMCID: PMC5557044.
      Citations: 4     Fields:    Translation:Humans
    91. Yust-Katz S, Mandel JJ, Wu J, Yuan Y, Webre C, Pawar TA, Lhadha HS, Gilbert MR, Armstrong TS. Venous thromboembolism (VTE) and glioblastoma. J Neurooncol. 2015 Aug; 124(1):87-94. PMID: 25985958.
      Citations: 16     Fields:    Translation:Humans
    92. Gong AH, Wei P, Zhang S, Yao J, Yuan Y, Zhou AD, Lang FF, Heimberger AB, Rao G, Huang S. FoxM1 Drives a Feed-Forward STAT3-Activation Signaling Loop That Promotes the Self-Renewal and Tumorigenicity of Glioblastoma Stem-like Cells. Cancer Res. 2015 Jun 01; 75(11):2337-48. PMID: 25832656; PMCID: PMC4452436.
      Citations: 48     Fields:    Translation:HumansAnimalsCells
    93. Shen W, Ning J, Yuan Y. Bayesian sequential monitoring design for two-arm randomized clinical trials with noncompliance. Stat Med. 2015 Jun 15; 34(13):2104-15. PMID: 25756852; PMCID: PMC4420650.
      Citations:    Fields:    Translation:Humans
    94. Shen W, Ning J, Yuan Y. A direct method to evaluate the time-dependent predictive accuracy for biomarkers. Biometrics. 2015 Jun; 71(2):439-49. PMID: 25758584; PMCID: PMC4479968.
      Citations: 6     Fields:    Translation:Humans
    95. Olar A, Wani KM, Alfaro-Munoz KD, Heathcock LE, van Thuijl HF, Gilbert MR, Armstrong TS, Sulman EP, Cahill DP, Vera-Bolanos E, Yuan Y, Reijneveld JC, Ylstra B, Wesseling P, Aldape KD. IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. Acta Neuropathol. 2015 Apr; 129(4):585-96. PMID: 25701198; PMCID: PMC4369189.
      Citations: 123     Fields:    Translation:HumansCells
    96. Liu S, Pan H, Xia J, Huang Q, Yuan Y. Bridging continual reassessment method for phase I clinical trials in different ethnic populations. Stat Med. 2015 May 10; 34(10):1681-94. PMID: 25626429.
      Citations: 8     Fields:    Translation:Humans
    97. Koul D, Yao J, Wan S, Yuan Y, Sulman E, Lang F, Yung WK, Colman H. Retraction: Novel HSP90 inhibitor NVP-HSP990 targets cell-cycle regulators to ablate Olig 2-positive glioma tumor-initiating cells. Cancer Res. 2014 Nov 15; 74(22):6731-2. PMID: 25398854; PMCID: PMC4381954.
      Citations:    Fields:    
    98. Vera-Bolanos E, Aldape K, Yuan Y, Wu J, Wani K, Necesito-Reyes MJ, Colman H, Dhall G, Lieberman FS, Metellus P, Mikkelsen T, Omuro A, Partap S, Prados M, Robins HI, Soffietti R, Wu J, Gilbert MR, Armstrong TS, CERN Foundation. Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients. Neuro Oncol. 2015 Mar; 17(3):440-7. PMID: 25121770; PMCID: PMC4483095.
      Citations: 52     Fields:    Translation:Humans
    99. Zang Y, Lee JJ, Yuan Y. Adaptive designs for identifying optimal biological dose for molecularly targeted agents. Clin Trials. 2014 06; 11(3):319-327. PMID: 24844841; PMCID: PMC4239216.
      Citations: 19     Fields:    Translation:Humans
    100. Pan H, Zhu C, Zhang F, Yuan Y, Zhang S, Zhang W, Li C, Wang L, Xia J. The continual reassessment method for multiple toxicity grades: a bayesian model selection approach. PLoS One. 2014; 9(5):e98147. PMID: 24875783; PMCID: PMC4038518.
      Citations: 2     Fields:    Translation:Humans
    101. Castillo SJ, Castillo R, Balter P, Pan T, Ibbott G, Hobbs B, Yuan Y, Guerrero T. Assessment of a quantitative metric for 4D CT artifact evaluation by observer consensus. J Appl Clin Med Phys. 2014 May 08; 15(3):4718. PMID: 24892346; PMCID: PMC4048877.
      Citations: 3     Fields:    Translation:Humans
    102. Yust-Katz S, de Groot JF, Liu D, Wu J, Yuan Y, Anderson MD, Conrad CA, Milbourne A, Gilbert MR, Armstrong TS. Pregnancy and glial brain tumors. Neuro Oncol. 2014 Sep; 16(9):1289-94. PMID: 24615863; PMCID: PMC4136891.
      Citations: 19     Fields:    Translation:Humans
    103. Liu S, Yuan Y, Castillo R, Guerrero T, Johnson VE. Evaluation of image registration spatial accuracy using a Bayesian hierarchical model. Biometrics. 2014 Jun; 70(2):366-77. PMID: 24575781; PMCID: PMC4061263.
      Citations: 1     Fields:    Translation:Humans
    104. Saito N, Fu J, Zheng S, Yao J, Wang S, Liu DD, Yuan Y, Sulman EP, Lang FF, Colman H, Verhaak RG, Yung WK, Koul D. A high Notch pathway activation predicts response to ? secretase inhibitors in proneural subtype of glioma tumor-initiating cells. Stem Cells. 2014 Jan; 32(1):301-12. PMID: 24038660; PMCID: PMC3947402.
      Citations: 72     Fields:    Translation:HumansAnimalsCells
    105. Yust-Katz S, Anderson MD, Liu D, Wu J, Yuan Y, Olar A, Fuller GN, Brown PD, de-Groot JF. Clinical and prognostic features of adult patients with gangliogliomas. Neuro Oncol. 2014 Mar; 16(3):409-13. PMID: 24305706; PMCID: PMC3922509.
      Citations: 13     Fields:    Translation:Humans
      Citations: 22     
    107. Ahn J, Liu S, Wang W, Yuan Y. Bayesian latent-class mixed-effect hybrid models for dyadic longitudinal data with non-ignorable dropouts. Biometrics. 2013 Dec; 69(4):914-24. PMID: 24328715; PMCID: PMC3970927.
      Citations: 1     Fields:    Translation:Humans
    108. Schover LR, Yuan Y, Fellman BM, Odensky E, Lewis PE, Martinetti P. Efficacy trial of an Internet-based intervention for cancer-related female sexual dysfunction. J Natl Compr Canc Netw. 2013 Nov; 11(11):1389-97. PMID: 24225972; PMCID: PMC3831175.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    109. Shinn EH, Basen-Engquist K, Baum G, Steen S, Bauman RF, Morrison W, Garden AS, Sheil C, Kilgore K, Hutcheson KA, Barringer D, Yuan Y, Lewin JS. Adherence to preventive exercises and self-reported swallowing outcomes in post-radiation head and neck cancer patients. Head Neck. 2013 Dec; 35(12):1707-12. PMID: 24142523; PMCID: PMC3943468.
      Citations: 39     Fields:    Translation:Humans
    110. Jin IH, Yuan Y, Liang F. Bayesian Analysis for Exponential Random Graph Models Using the Adaptive Exchange Sampler. Stat Interface. 2013 Oct 01; 6(4):559-576. PMID: 24653788; PMCID: PMC3956133.
    111. Yuan Y, Mackinnon DP. Robust mediation analysis based on median regression. Psychol Methods. 2014 Mar; 19(1):1-20. PMID: 24079925; PMCID: PMC3969875.
      Citations: 8     Fields:    Translation:Humans
    112. Zang Y, Yuan Y. A shrinkage method for testing the Hardy-Weinberg equilibrium in case-control studies. Genet Epidemiol. 2013 Nov; 37(7):743-50. PMID: 23934751; PMCID: PMC3972031.
      Citations:    Fields:    Translation:Humans
    113. Yust-Katz S, Garciarena P, Liu D, Yuan Y, Ibrahim N, Yerushalmi R, Penas-Prado M, Groves MD. Breast cancer and leptomeningeal disease (LMD): hormone receptor status influences time to development of LMD and survival from LMD diagnosis. J Neurooncol. 2013 Sep; 114(2):229-35. PMID: 23756727.
      Citations: 21     Fields:    Translation:Humans
    114. Ahn J, Yuan Y, Parmigiani G, Suraokar MB, Diao L, Wistuba II, Wang W. DeMix: deconvolution for mixed cancer transcriptomes using raw measured data. Bioinformatics. 2013 Aug 01; 29(15):1865-71. PMID: 23712657; PMCID: PMC3841439.
      Citations: 42     Fields:    Translation:HumansAnimals
    115. Yust-Katz S, Liu D, Yuan Y, Liu V, Kang S, Groves M, Puduvalli V, Levin V, Conrad C, Colman H, Hsu S, Yung WK, Gilbert MR. Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma. Cancer. 2013 Aug 01; 119(15):2747-53. PMID: 23633392; PMCID: PMC4001735.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    116. Fu J, Koul D, Yao J, Wang S, Yuan Y, Colman H, Sulman EP, Lang FF, Yung WK. Novel HSP90 inhibitor NVP-HSP990 targets cell-cycle regulators to ablate Olig2-positive glioma tumor-initiating cells. Cancer Res. 2013 May 15; 73(10):3062-74. PMID: 23492364; PMCID: PMC3655088.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    117. Cai C, Yuan Y, Johnson VE. Bayesian adaptive phase II screening design for combination trials. Clin Trials. 2013; 10(3):353-62. PMID: 23359875; PMCID: PMC3867529.
      Citations: 3     Fields:    Translation:Humans
    118. Yao J, Zhao Q, Yuan Y, Zhang L, Liu X, Yung WK, Weinstein JN. Identification of common prognostic gene expression signatures with biological meanings from microarray gene expression datasets. PLoS One. 2012; 7(9):e45894. PMID: 23029298; PMCID: PMC3448701.
      Citations: 9     Fields:    Translation:HumansCells
    119. Fingeret MC, Hutcheson KA, Jensen K, Yuan Y, Urbauer D, Lewin JS. Associations among speech, eating, and body image concerns for surgical patients with head and neck cancer. Head Neck. 2013 Mar; 35(3):354-60. PMID: 22431304; PMCID: PMC4022133.
      Citations: 27     Fields:    Translation:Humans
    120. Younes A, Oki Y, McLaughlin P, Copeland AR, Goy A, Pro B, Feng L, Yuan Y, Chuang HH, Macapinlac HA, Hagemeister F, Romaguera J, Samaniego F, Fanale MA, Dabaja BS, Rodriguez MA, Dang N, Kwak LW, Neelapu SS, Fayad LE. Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood. 2012 May 03; 119(18):4123-8. PMID: 22371887; PMCID: PMC3359733.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    121. Jiang X, Yuan YP, Xu DT, Zhang B, Liu YL. [Influences of diagnostic modes on an early diagnosis of colorectal cancer]. Zhonghua Yi Xue Za Zhi. 2011 Nov 08; 91(41):2886-90. PMID: 22333606.
      Citations: 1     Fields:    Translation:Humans
    122. Koul D, Fu J, Shen R, LaFortune TA, Wang S, Tiao N, Kim YW, Liu JL, Ramnarian D, Yuan Y, Garcia-Echevrria C, Maira SM, Yung WK. Antitumor activity of NVP-BKM120--a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells. Clin Cancer Res. 2012 Jan 01; 18(1):184-95. PMID: 22065080; PMCID: PMC3785365.
      Citations: 80     Fields:    Translation:HumansAnimalsCells
    123. Yuan Y, Johnson VE. Goodness-of-fit diagnostics for Bayesian hierarchical models. Biometrics. 2012 Mar; 68(1):156-64. PMID: 22050079; PMCID: PMC3276744.
      Citations: 7     Fields:    
    124. Schover LR, Canada AL, Yuan Y, Sui D, Neese L, Jenkins R, Rhodes MM. A randomized trial of internet-based versus traditional sexual counseling for couples after localized prostate cancer treatment. Cancer. 2012 Jan 15; 118(2):500-9. PMID: 21953578; PMCID: PMC4022136.
      Citations: 64     Fields:    Translation:Humans
    125. Yuan Y, Yin G. Robust EM Continual Reassessment Method in Oncology Dose Finding. J Am Stat Assoc. 2011 Sep 01; 106(495):818-831. PMID: 22375092; PMCID: PMC3286608.
      Citations: 18     
    126. Fingeret MC, Yuan Y, Urbauer D, Weston J, Nipomnick S, Weber R. The nature and extent of body image concerns among surgically treated patients with head and neck cancer. Psychooncology. 2012 Aug; 21(8):836-44. PMID: 21706673; PMCID: PMC5094055.
      Citations: 53     Fields:    Translation:Humans
    127. Yuan Y, Yin G. Dose-response curve estimation: a semiparametric mixture approach. Biometrics. 2011 Dec; 67(4):1543-54. PMID: 21627631.
      Citations: 5     Fields:    Translation:HumansAnimals
    128. Carmack CL, Basen-Engquist K, Yuan Y, Greisinger A, Rodriguez-Bigas M, Wolff RA, Barker T, Baum G, Pennebaker JW. Feasibility of an expressive-disclosure group intervention for post-treatment colorectal cancer patients: results of the Healthy Expressions study. Cancer. 2011 Nov 01; 117(21):4993-5002. PMID: 21480203.
      Citations: 16     Fields:    Translation:Humans
    129. Yuan Y, Huang X, Liu S. A Bayesian response-adaptive covariate-balanced randomization design with application to a leukemia clinical trial. Stat Med. 2011 May 20; 30(11):1218-29. PMID: 21432894; PMCID: PMC3086983.
      Citations: 7     Fields:    Translation:Humans
    130. Yuan Y, Yin G. On the usefulness of outcome-adaptive randomization. J Clin Oncol. 2011 May 01; 29(13):e390-2; author reply e393. PMID: 21422433.
      Citations: 8     Fields:    Translation:Humans
    131. Yuan Y, Yin G. Bayesian hybrid dose-finding design in phase I oncology clinical trials. Stat Med. 2011 Jul 30; 30(17):2098-108. PMID: 21365672; PMCID: PMC3286188.
      Citations: 6     Fields:    Translation:Humans
    132. Le-Petross HT, Whitman GJ, Atchley DP, Yuan Y, Gutierrez-Barrera A, Hortobagyi GN, Litton JK, Arun BK. Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer. Cancer. 2011 Sep 01; 117(17):3900-7. PMID: 21365619.
      Citations: 23     Fields:    Translation:Humans
    133. Yuan Y, Yin G. BAYESIAN PHASE I/II ADAPTIVELY RANDOMIZED ONCOLOGY TRIALS WITH COMBINED DRUGS. Ann Appl Stat. 2011 Jan 01; 5(2A):924-942. PMID: 22375162; PMCID: PMC3286607.
      Citations: 26     
    134. Lei X, Yuan Y, Yin G. Bayesian phase II adaptive randomization by jointly modeling time-to-event efficacy and binary toxicity. Lifetime Data Anal. 2011 Jan; 17(1):156-74. PMID: 20364321.
      Citations: 2     Fields:    Translation:Humans
    135. Yuan Y, MacKinnon DP. Bayesian mediation analysis. Psychol Methods. 2009 Dec; 14(4):301-22. PMID: 19968395; PMCID: PMC2885293.
      Citations: 85     Fields:    Translation:Humans
    136. Kiserud CE, Schover LR, Dahl AA, Holte H, Yuan Y, Foss? A, Bj?ro T, Loge JH, Foss? SD. Do male lymphoma survivors have impaired sexual function? J Clin Oncol. 2009 Dec 10; 27(35):6019-26. PMID: 19858388.
      Citations: 13     Fields:    Translation:Humans
    137. Yuan Y, Little RJ. Mixed-effect hybrid models for longitudinal data with nonignorable dropout. Biometrics. 2009 Jun; 65(2):478-86. PMID: 18759842.
      Citations: 9     Fields:    
    138. Yuan Y, Yin G. Bayesian quantile regression for longitudinal studies with nonignorable missing data. Biometrics. 2010 Mar; 66(1):105-14. PMID: 19459836.
      Citations: 11     Fields:    
    139. Yuan Y, Yin G. Sequential continual reassessment method for two-dimensional dose finding. Stat Med. 2008 Nov 29; 27(27):5664-78. PMID: 18618901.
      Citations: 22     Fields:    Translation:Humans
    140. Yin G, Yuan Y. A latent contingency table approach to dose finding for combinations of two agents. Biometrics. 2009 Sep; 65(3):866-75. PMID: 18759848.
      Citations: 30     Fields:    Translation:Humans
    141. Song PX, Li M, Yuan Y. Joint regression analysis of correlated data using Gaussian copulas. Biometrics. 2009 Mar; 65(1):60-8. PMID: 18510653.
      Citations: 20     Fields:    
    142. Yuan Y, Little RJ. Meta-analysis of studies with missing data. Biometrics. 2009 Jun; 65(2):487-96. PMID: 18565168.
      Citations: 7     Fields:    
    143. Gao Y, Zhong WX, Mu DB, Yuan YP, Zhang YH, Yu JM, Sun LP, Wang L, Li YH, Zhang JB, Zhao Y, Cai SP, Zhou GY. Distributions of angiogenesis and lymphangiogenesis in gastrointestinal intramucosal tumors. Ann Surg Oncol. 2008 Apr; 15(4):1117-23. PMID: 18202892.
      Citations: 7     Fields:    Translation:Humans
    144. Kolker JL, Yuan Y, Burt BA, Sandretto AM, Sohn W, Lang SW, Ismail AI. Dental caries and dietary patterns in low-income African American children. Pediatr Dent. 2007 Nov-Dec; 29(6):457-64. PMID: 18254414.
      Citations: 22     Fields:    Translation:HumansPHPublic Health
    145. Yuan Y, Little RJ. Parametric and semiparametric model-based estimates of the finite population mean for two-stage cluster samples with item nonresponse. Biometrics. 2007 Dec; 63(4):1172-80. PMID: 17489967.
      Citations: 2     Fields:    
    146. Johnson V, Yuan Y. Comments on 'An exploratory test for an excess of significant findings' by JPA loannidis and TA Trikalinos. Clin Trials. 2007; 4(3):254-5; discussion 256-7. PMID: 17715250.
      Citations: 4     Fields:    Translation:Humans
    147. Gao P, Zhou GY, Zhang QH, Li H, Mu K, Yuan YP, Zhang J, Wang BH. Reversal MDR in breast carcinoma cells by transfection of ribozyme designed according the secondary structure of mdr1 mRNA. Chin J Physiol. 2006 Apr 30; 49(2):96-103. PMID: 16830791.
      Citations:    Fields:    Translation:HumansCells
    148. Scherer SE, Muzny DM, Buhay CJ, Chen R, Cree A, Ding Y, Dugan-Rocha S, Gill R, Gunaratne P, Harris RA, Hawes AC, Hernandez J, Hodgson AV, Hume J, Jackson A, Khan ZM, Kovar-Smith C, Lewis LR, Lozado RJ, Metzker ML, Milosavljevic A, Miner GR, Montgomery KT, Morgan MB, Nazareth LV, Scott G, Sodergren E, Song XZ, Steffen D, Lovering RC, Wheeler DA, Worley KC, Yuan Y, Zhang Z, Adams CQ, Ansari-Lari MA, Ayele M, Brown MJ, Chen G, Chen Z, Clerc-Blankenburg KP, Davis C, Delgado O, Dinh HH, Draper H, Gonzalez-Garay ML, Havlak P, Jackson LR, Jacob LS, Kelly SH, Li L, Li Z, Liu J, Liu W, Lu J, Maheshwari M, Nguyen BV, Okwuonu GO, Pasternak S, Perez LM, Plopper FJ, Santibanez J, Shen H, Tabor PE, Verduzco D, Waldron L, Wang Q, Williams GA, Zhang J, Zhou J, Allen CC, Amin AG, Anyalebechi V, Bailey M, Barbaria JA, Bimage KE, Bryant NP, Burch PE, Burkett CE, Burrell KL, Calderon E, Cardenas V, Carter K, Casias K, Cavazos I, Cavazos SR, Ceasar H, Chacko J, Chan SN, Chavez D, Christopoulos C, Chu J, Cockrell R, Cox CD, Dang M, Dathorne SR, David R, Davis CM, Davy-Carroll L, Deshazo DR, Donlin JE, D'Souza L, Eaves KA, Egan A, Emery-Cohen AJ, Escotto M, Flagg N, Forbes LD, Gabisi AM, Garza M, Hamilton C, Henderson N, Hernandez O, Hines S, Hogues ME, Huang M, Idlebird DG, Johnson R, Jolivet A, Jones S, Kagan R, King LM, Leal B, Lebow H, Lee S, LeVan JM, Lewis LC, London P, Lorensuhewa LM, Loulseged H, Lovett DA, Lucier A, Lucier RL, Ma J, Madu RC, Mapua P, Martindale AD, Martinez E, Massey E, Mawhiney S, Meador MG, Mendez S, Mercado C, Mercado IC, Merritt CE, Miner ZL, Minja E, Mitchell T, Mohabbat F, Mohabbat K, Montgomery B, Moore N, Morris S, Munidasa M, Ngo RN, Nguyen NB, Nickerson E, Nwaokelemeh OO, Nwokenkwo S, Obregon M, Oguh M, Oragunye N, Oviedo RJ, Parish BJ, Parker DN, Parrish J, Parks KL, Paul HA, Payton BA, Perez A, Perrin W, Pickens A, Primus EL, Pu LL, Puazo M, Quiles MM, Quiroz JB, Rabata D, Reeves K, Ruiz SJ, Shao H, Sisson I, Sonaike T, Sorelle RP, Sutton AE, Svatek AF, Svetz LA, Tamerisa KS, Taylor TR, Teague B, Thomas N, Thorn RD, Trejos ZY, Trevino BK, Ukegbu ON, Urban JB, Vasquez LI, Vera VA, Villasana DM, Wang L, Ward-Moore S, Warren JT, Wei X, White F, Williamson AL, Wleczyk R, Wooden HS, Wooden SH, Yen J, Yoon L, Yoon V, Zorrilla SE, Nelson D, Kucherlapati R, Weinstock G, Gibbs RA, Baylor College of Medicine Human Genome Sequencing Center Sequence Production Team, Simons R. The finished DNA sequence of human chromosome 12. Nature. 2006 03 16; 440(7082):346-51. PMID: 16541075.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    149. Burt BA, Kolker JL, Sandretto AM, Yuan Y, Sohn W, Ismail AI. Dietary patterns related to caries in a low-income adult population. Caries Res. 2006; 40(6):473-80. PMID: 17063017; PMCID: PMC1626651.
      Citations: 17     Fields:    Translation:Humans
    150. Zhou J, Yuan Y, Reynolds R, Raber S, Li Y. Cost-efficient higher-order crossover designs in comparative bioavailability studies. Clin Pharmacokinet. 2006; 45(6):623-32. PMID: 16719543.
      Citations: 1     Fields:    
    151. The relationship between corticosteroids and symptoms in patients with primary brain tumors. Neuro-Oncology. 17:1114-1120.
    152. A practical Bayesian design to identify the maximum tolerated dose contour for drug combination trials. Statistics in Medicine. 35:4924-4936.
    153. Bayesian dose finding in oncology for drug combinations by copula regression. Journal of the Royal Statistical Society. Series C: Applied Statistics. 59:544-546.
    154. A Bayesian phase I/II clinical trial design in the presence of informative dropouts. Statistics and its Interface. 8:217-226.
    155. Utility-based designs for randomized comparative trials with categorical outcomes. Statistics in Medicine. 35:4285-4305.
    156. Bayesian phase I/II adaptively randomized oncology trials with combined drugs. Annals of Applied Statistics. 5:924-942.
    157. A dose-schedule finding design for phase I-II clinical trials. Journal of the Royal Statistical Society. Series C: Applied Statistics.
    158. Assessment of a quantitative metric for 4D CT artifact evaluation by observer consensus. Journal of Applied Clinical Medical Physics. 15:190-201.
    159. A Bayesian design for phase II clinical trials with delayed responses based on multiple imputation. Statistics in Medicine. 33:4017-4028.
    160. Bayesian analysis for exponential random graph models using the adaptive exchange sampler. Statistics and its Interface. 6:559-576.
    161. Screening adherence and cancer risk perceptions in colorectal cancer survivors with Lynch-like syndrome. Clinical Genetics. 89:392-398.
    162. Journal of the American Statistical Association. 109:525-536.
    163. Long non-coding RNA profiling links subgroup classification of endometrioid endometrial carcinomas with trithorax and polycomb complex aberrations. Oncotarget. 6:39865-39876.
    164. Bayesian dose finding in oncology for drug combinations by copula regression. Journal of the Royal Statistical Society. Series C: Applied Statistics. 58:211-224.
    165. Localization of breast sentinel lymph nodes by MR lymphography with a conventional gadolinium contrast agent. Breast Diseases. 15:37.
    166. Bayesian dose finding for combined drugs with discrete and continuous doses. Bayesian Analysis. 7:1035-1052.
    167. Bayesian hypothesis tests using nonparametric statistics. Statistica Sinica. 18:1185-1200.
    168. Rejoinder to "Joint Regression Analysis for Discrete Longitudinal Data" by Madsen and Fang. Biometrics. 67:1175-1176.
    169. Model-based estimates of the finite population mean for two-stage cluster samples with unit non-response. Journal of the Royal Statistical Society. Series C: Applied Statistics. 56:79-97.
    170. Estimating progression-free survival in paediatric brain tumour patients when some progression statuses are unknown. Journal of the Royal Statistical Society. Series C: Applied Statistics. 61:135-149.
    171. Optimal sequential enrichment designs for phase II clinical trials. Statistics in Medicine. 36:54-66.
    172. Optimal marker-strategy clinical trial design to detect predictive markers for targeted therapy. Biostatistics. 17:549-560.
    173. Bayesian optimal interval designs for phase I clinical trials. Journal of the Royal Statistical Society. Series C: Applied Statistics. 64:507-523.
    174. Identification of recurrent focal copy number variations and their putative targeted driver genes in ovarian cancer. BMC Bioinformatics. 17.
    175. Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression. Blood Cancer Journal. 4.
    176. Characterization of long non-coding RNA transcriptome in clear-cell renal cell carcinoma by next-generation deep sequencing. Molecular Oncology. 9:32-43.
    177. Bayesian optimal interval design. Clinical Cancer Research. 22:4291-4301.
    178. Cancer screening behaviors and risk perceptions among family members of colorectal cancer patients with unexplained mismatch repair deficiency. Familial Cancer. 1-7.
    179. Bayesian sequential monitoring design for two-arm randomized clinical trials with noncompliance. Statistics in Medicine. 34:2104-2115.
    180. A default method to specify skeletons for Bayesian model averaging continual reassessment method for phase I clinical trials. Statistics in Medicine.
    181. Expression of Bcl-xL gene in human thyroid carcinoma and its significance. Chinese Journal of Cancer Prevention and Treatment. 15:652-654.
    182. Bayesian model averaging continual reassessment method in phase I clinical trials. Journal of the American Statistical Association. 104:954-968.
    183. A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients. Journal of Neuro-Oncology.
    184. A Bayesian dose finding design for clinical trials combining a cytotoxic agent with a molecularly targeted agent. Journal of the Royal Statistical Society. Series C: Applied Statistics. 64:215-229.
    185. An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma. Journal of Neuro-Oncology. 123:85-91.
    186. Two-stage marker-stratified clinical trial design in the presence of biomarker misclassification. Journal of the Royal Statistical Society. Series C: Applied Statistics. 65:585-601.
    187. A Bayesian hierarchical spatial model for dental caries assessment using non-Gaussian Markov random fields. Annals of Applied Statistics. 10:884-905.
    188. Stochastic generalized method of moments. Journal of Computational and Graphical Statistics. 20:714-727.
    189. A calibrated power prior approach to borrow information from historical data with application to biosimilar clinical trials. Journal of the Royal Statistical Society. Series C: Applied Statistics.
    190. Rate-adaptive bayesian independent component analysis. Electronic Journal of Statistics. 10:3247-3264.
    191. Adaptive designs for identifying optimal biological dose for molecularly targeted agents. Clinical Trials. 11:319-327.
    192. Bayesian modeling longitudinal dyadic data with nonignorable dropout, with application to a breast cancer study. Annals of Applied Statistics. 6:753-771.
    193. Bayesian dose finding by jointly modelling toxicity and efficacy as time-to-event outcomes. Journal of the Royal Statistical Society. Series C: Applied Statistics. 58:719-736.
    194. Optimal marker-adaptive designs for targeted therapy based on imperfectly measured biomarkers. Journal of the Royal Statistical Society. Series C: Applied Statistics. 64:635-650.
    195. Robust EM continual reassessment method in oncology dose finding. Journal of the American Statistical Association. 106:818-831.
    196. Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients. Neuro-Oncology. 17:440-447.
    197. A Bayesian dose finding design for oncology clinical trials of combinational biological agents. Journal of the Royal Statistical Society. Series C: Applied Statistics. 63:159-173.
    198. A direct method to evaluate the time-dependent predictive accuracy for biomarkers. Biometrics. 71:439-449.
    199. Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity. Annals of Applied Statistics. 7:2138-2156.
    200. Adaptive dose modification for phase I clinical trials. Statistics in Medicine.
    201. Outcome of patients with malignant glioma and synchronous or metachronous non-central nervous system primary neoplasms. Journal of Neuro-Oncology. 126:527-533.
    YUAN's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (487)
    Co-Authors (220)
    Similar People (60)
    Same Department Expand Description